As expected, the expressions of CSCs marker gene CD44, Sox2 and β-catenin were decreased in PKMYT1AR targeting ASOs groups, indicating the promising therapeutic effect treating NSCLC patients in the future (Fig. S9j-k). Here, SOX2 is linked to non-small cell lung carcinoma.